Health knowledge made personal
Join this community!
› Share page:
Search posts:

Identification of New Malaria Parasite Erythrocyte Binding Protein (BAEBL) that Binds to Human Red Cells

Posted Feb 27 2011 7:00pm

Description of Invention:
Malaria is endemic in many parts of the world, particularly in tropical regions such as Asia, Central America and South America. Recent estimates of the number of cases of malaria worldwide are between five hundred million and one billion. There are approximately two to three hundred million new cases of malaria each year and malaria causes a minimum of one million deaths each year. This invention relates to the identification and characterization of the binding specificity of BAEBL, a novel Plasmodium falciparum erythrocyte binding ligand that interacts with human erythrocytes in a sialic acid dependent manner. This novel Plasmodium falciparum erythrocyte binding ligand is unique and quite distinct from previously described Plasmodium falciparum erythrocyte binding proteins EBA-175. BAEBL may be used as a malaria vaccine to block human red cell recognition and invasion.

Ghislaine D Mayer (NIAID)
Louis H Miller (NIAID)

Patent Status:
HHS, Reference No. E-328-2000/0

Infectious Diseases
Infectious Diseases - Vaccines

For Licensing Information Please Contact:
Admin. Licensing Spec-InfectDis
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-496-7057
Fax: 301-402-0220

Ref No: 469

Updated: 02/2011

Post a comment
Write a comment:

Related Searches